Go Pro

CONMED (CNMD) Stock Price, News & Analysis

CONMED logo
$49.30 -0.13 (-0.26%)
Closing price 09/3/2026 03:58 PM Eastern
Extended Trading
$49.42 +0.12 (+0.24%)
As of 09:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About CONMED Stock (NYSE:CNMD)

Advanced

Key Stats

Today's Range
$48.50
$50.33
50-Day Range
$32.68
$51.93
52-Week Range
$31.44
$56.63
Volume
221,725 shs
Average Volume
323,880 shs
Market Capitalization
$1.48 billion
P/E Ratio
26.65
Dividend Yield
N/A
Price Target
$41.40
Consensus Rating
Reduce

Company Overview

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy. The Orthopedics segment offers arthroscopic shavers, burrs and handpieces, as well as joint repair and reconstruction implants. In its Visualization & Energy segment, CONMED provides endoscopic imaging systems, electrosurgical and radiofrequency generators, insufflators, ablation devices and related disposables. These technologies are designed to improve procedural efficiency, safety and patient outcomes.

With a presence in over 70 countries, CONMED sells products through direct sales forces as well as distributor partnerships. The company’s international footprint spans North America, Europe, Latin America, Asia Pacific and select emerging markets. CONMED works closely with healthcare facilities and surgical centers to deliver training, technical support and service solutions tailored to local regulatory requirements and clinical practices.

Leadership at CONMED includes President and Chief Executive Officer Jeffrey M. Dunn, whose tenure has focused on strategic growth through product innovation and targeted acquisitions. Over its history, the company has expanded both organically and via the integration of complementary businesses to broaden its capabilities in key procedural areas. CONMED remains committed to advancing minimally invasive surgical technologies and supporting clinicians worldwide.

AI Generated. May Contain Errors.

CONMED Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

CNMD MarketRank™: 

CONMED scored higher than 33% of companies evaluated by MarketBeat, and ranked 747th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CONMED has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no strong buy ratings, no buy ratings, 6 hold ratings, and 2 sell ratings.

  • Downside Risk

    CONMED has a consensus price target of $41.40, representing about 16.0% downside from its current price of $49.30.

  • Amount of Analyst Coverage

    CONMED has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about CONMED's stock forecast and price target.
  • Earnings Growth

    Earnings for CONMED are expected to grow by 4.19% in the coming year, from $4.54 to $4.73 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CONMED is 26.65, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.27.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CONMED is 26.65, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.30.

  • Price to Earnings Growth Ratio

    CONMED has a PEG Ratio of 2.25. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    CONMED has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about CONMED's valuation and earnings.
  • Percentage of Shares Shorted

    7.77% of the float of CONMED has been sold short.
  • Short Interest Ratio / Days to Cover

    CONMED has a short interest ratio ("days to cover") of 5.01.
  • Change versus previous month

    Short interest in CONMED has recently increased by 3.80%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    CONMED does not currently pay a dividend.

  • Dividend Growth

    CONMED does not have a long track record of dividend growth.

  • Dividend Sustainability

    Based on earnings estimates, CONMED will have a dividend payout ratio of 12.68% next year. This indicates that CONMED will be able to sustain or increase its dividend.

  • News Sentiment

    CONMED has a news sentiment score of 1.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for CONMED this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, CONMED insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    0.28% of the stock of CONMED is held by insiders.

  • Percentage Held by Institutions

    CONMED has minimal institutional ownership at this time.

  • Read more about CONMED's insider trading history.
Receive CNMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CONMED and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CNMD Stock News Headlines

Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25.tc pixel
CONMED Corp (CNMD) Q2 2026 Earnings
Conmed: Q2 Earnings Snapshot
See More Headlines

CNMD Stock Analysis - Frequently Asked Questions

CONMED's stock was trading at $40.56 on January 1st, 2026. Since then, CNMD stock has increased by 21.5% and is now trading at $49.30.

CONMED Corporation (NYSE:CNMD) announced its quarterly earnings results on Wednesday, July, 29th. The company reported $1.38 earnings per share for the quarter, beating analysts' consensus estimates of $1.11 by $0.27. CONMED's quarterly revenue was up .3% on a year-over-year basis.
Read the conference call transcript
.

Top institutional investors of CONMED include BlackRock Inc. (16.10%), Bank of America Corp DE (4.48%), California State Teachers Retirement System (3.61%) and Paradigm Capital Management Inc. NY (1.80%). Insiders that own company stock include Charles Farkas, Pat Beyer, Martha Goldberg Aronson, Barbara J Schwarzentraub, Stanley W Peters III and Richard Glaze.
View institutional ownership trends
.

Shares of CNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CONMED investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
7/29/2026
Today
9/04/2026
Wells Fargo 21st Annual Healthcare Conference
9/09/2026
Next Earnings (Estimated)
11/04/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NYSE:CNMD
CIK
816956
Employees
3,900
Year Founded
1970

Price Target and Rating

High Price Target
$46.00
Low Price Target
$36.00
Potential Upside/Downside
-16.0%
Consensus Rating
Reduce
Rating Score (0-4)
1.75
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.85
Trailing P/E Ratio
26.65
Forward P/E Ratio
10.86
P/E Growth
2.25
Net Income
$47.06 million
Net Margins
4.12%
Pretax Margin
6.07%
Return on Equity
14.31%
Return on Assets
6.33%

Debt

Debt-to-Equity Ratio
0.63
Current Ratio
1.48
Quick Ratio
0.69

Sales & Book Value

Annual Sales
$1.37 billion
Price / Sales
1.07
Cash Flow
$7.19 per share
Price / Cash Flow
6.86
Book Value
$34.77 per share
Price / Book
1.42

Miscellaneous

Outstanding Shares
29,950,000
Free Float
29,867,000
Market Cap
$1.48 billion
Optionable
Optionable
Beta
0.90

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NYSE:CNMD) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners